Amy Bricker was appointed Director of MiniMed Group, Inc., effective October 15, 2026. As of November 7, 2026, MiniMed Group, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 18, 2026 to October 16, 2026, naming 4 appointments and 1 departure (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like MiniMed Group, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Amy Bricker · Role: Director · Effective: 2026-10-15 · 8-K, 2026-10-16
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-05
- · In / out: In · Person: David Endicott · Role: Director · Effective: 2026-06-29 · 8-K, 2026-06-29
- · In / out: Out · Person: Brett Wall · Role: Director · Effective: 2026-07-03 · 8-K, 2026-05-18
MiniMed Group, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-18 to 2026-10-16. They name 5 people, with 4 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as MiniMed Group, Inc. files it.
Also on the record for MiniMed Group, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 13.5% of the class | 5%+ stakes | Source |
| October 22, 2026 | Stake report, Schedule 13G, by Capital Ventures International | 7.8% of the class | 5%+ stakes | Source |
| October 16, 2026 | Stake report, Schedule 13G/A, by Medtronic plc | — | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by Medtronic plc | 90% of the class | 5%+ stakes | Source |
| March 6, 2026 | IPO filing, Form 424B4 | $20 a share | IPO filings | Source |
| February 27, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 24, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 23, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 19, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs MiniMed Group, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on MiniMed Group, Inc. and the records around it.
MiniMed Group, Inc. elsewhere on the record
Companies that share a holder
- Medtronic plc also filed stake reports on 2 other companies: Orchestra BioMed Holdings, Inc. (Feb 2026), Anteris Technologies Global Corp. (Jan 2026)
- Capital Ventures International also filed stake reports on 6 other companies: Luminar Technologies, Inc. (Aug 2026), NextNav Inc. (Aug 2026), Super Micro Computer, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch MiniMed Group, Inc.
Get an email when MiniMed Group, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MiniMed Group, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MiniMed Group, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MiniMed Group, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | In | Director | 2026-10-15 | 8-K, 2026-10-16 | |
| 2026-08-05 | Reported | not named in the filing | 8-K, 2026-08-05 | ||
| 2026-06-29 | In | Director | 2026-06-29 | 8-K, 2026-06-29 | |
| 2026-06-29 | In | Director | 8-K, 2026-06-29 | ||
| 2026-05-18 | Out | Director | 2026-07-03 | 8-K, 2026-05-18 | |
| 2026-05-18 | In | Director | 2026-07-03 | 8-K, 2026-05-18 |
Who leads MiniMed Group, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Amy Bricker, appointed, effective 2026-10-15 (filed 2026-10-16).
New leaders reset buying decisions — get the Full Report on MiniMed Group, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at MiniMed Group, Inc., with the record behind each one.
Find candidates like Director at MiniMed Group, Inc.Every change, in the filing's words
Appointed: Amy Bricker, Director, effective 2026-10-15
Director Appointment In connection with the Resignations, on October 15, 2026, the Board decreased the size of the Board from 11 to eight and appointed Amy Bricker to serve as a director of the Board to fill the resulting vacancy, effective October 15, 2026.
- Director Resignations In connection with the completion of the Exchange Offer, Linnea Burman, Scott Cundy, Laura Mauri, and Matthew R. Walter each resigned from MiniMed's Board of Directors (the "Board"), effective October 15, 2026 (the "Resignations").
- None of the Resignations are the result of any disagreement with management or the Board related to MiniMed's operations, policies or practices.
- Ms. Bricker will serve as a Class II director whose term expires at the 2027 annual meeting of stockholders and will be a member of the Board's Nominating and Corporate Governance Committee.
- Ms. Bricker currently serves as Executive Vice President, Chief Enterprise Pharmacy Officer of Walgreen Co., a role she has held since 2025.
- Prior to joining Walgreen Co., Ms. Bricker was employed at different healthcare organizations, including CVS Health Corporation (NYSE: CVS) from 2023 to 2024, and Express Scripts (NYSE: CI) from 2010 to 2023, including as President from 2020 to 2023.
- Ms. Bricker holds a B.S. from the University of Health Sciences and Pharmacy in St. Louis.
- The Board has determined that Ms. Bricker is "independent" in accordance with the rules of The Nasdaq Stock Market LLC, the SEC, and MiniMed's corporate governance guidelines.
Reported
On July 30, 2026, Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, notified MiniMed Group, Inc. ("MiniMed") of her decision to resign from her position, effective September 25, 2026, following an 8-week transition period.
- Ms. Nelson Wills's departure is for personal reasons, as she has accepted a role outside the medical device space, and is not the result of any disagreement with MiniMed.
- MiniMed is conducting a search for a successor, appreciates Ms. Nelson Wills's helpful assistance in facilitating a seamless leadership transition of her duties, and remains committed to maintaining strong legal, governance, and compliance oversight throughout this transition.
- These risks and uncertainties are described in MiniMed's filings with the U.S. Securities and Exchange Commission.
- Actual results may differ materially from anticipated results.
Appointed: David Endicott, Director, effective 2026-06-29
On June 25, 2026, the Board of Directors (the "Board") of MiniMed Group, Inc. ("MiniMed") increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
Appointed: Linnea Burman, Director
Ms. Burman will serve as a class II director whose term expires at the 2027 annual meeting of stockholders.
- Mr. Endicott will serve as a class I director whose term expires at the 2026 annual meeting of stockholders and will be a member of the Board's Compensation and Talent Committee.
- Mr. Endicott currently serves as Chief Executive Officer of Alcon, Inc. (NYSE: ALC; SWX: ALC), an eye care company, and has served as a member of Alcon's board of directors since 2019.
- Prior to joining Alcon, Inc., Mr. Endicott held senior leadership roles at various healthcare organizations, including as Chief Executive Officer and Chief Operating Officer of Alcon Laboratories, Inc., President of Hospira Infusion Systems at Hospira, Inc., and various commercial and regional leadership roles at Allergan, Inc. Mr. Endicott holds an M.B.A. from the University of Southern California and a B.A. in Chemistry from Whitman College.
- The Board has determined that Mr. Endicott is "independent" in accordance with the rules of The Nasdaq Stock Market LLC, the Securities and Exchange Commission (the "SEC") and MiniMed's corporate governance guidelines.
- Ms. Burman currently serves as Senior Vice President & President, Neurovascular at Medtronic plc ("Medtronic").
- From May 2020 to May 2024, Ms. Burman served as Vice President & General Manager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic.
Departing: Brett Wall, Director, effective 2026-07-03
On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the "Board") of MiniMed Group, Inc. ("MiniMed") and member of the Board's Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026.
Appointed: Scott Cundy, Director, effective 2026-07-03
On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall's departure.
- His decision to resign is not the result of any disagreement with management or the Board related to MiniMed's operations, policies, or practices.
- His decision to resign results from his departure as Executive Vice President and President, Neuroscience Portfolio, of Medtronic plc ("Medtronic"), the parent company of MiniMed, which nominated Mr. Wall as a member of the Board.
- Mr. Cundy will serve as class II director whose term expires at the 2027 annual meeting of stockholders and will be a member of the Board's Nominating and Corporate Governance Committee.
- Mr. Cundy currently serves as Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic, leads the Global Quality, Product Development, and Innovation functions at Medtronic and is a member of the Medtronic Executive Committee.
- Mr. Cundy also oversees the Medtronic Engineering and Innovation Center.
- Prior to joining Medtronic in 2023, Mr. Cundy served as Vice President Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation.
- Mr. Cundy holds a B.S. in Industrial Engineering from Georgia Institute of Technology and an MBA from the University of Minnesota's Carlson School of Management.
- For so long as Medtronic is an affiliate of MiniMed, Mr. Cundy, as an employee of Medtronic, will receive no compensation for his service on the Board.
Tools for this story
Each opens in a new tab, filled in for MiniMed Group, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.